Growing community of inventors

Vif, France

Catherine Pillet

Average Co-Inventor Count = 7.20

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Catherine PilletCaroline Barette (2 patents)Catherine PilletEmmanuelle Soleilhac (2 patents)Catherine PilletClaude Cochet (1 patent)Catherine PilletOdile Filhol (1 patent)Catherine PilletMarie-Odile Fauvarque (1 patent)Catherine PilletMagda Mortier (1 patent)Catherine PilletCarmen Aguilar (1 patent)Catherine PilletVincent Remusat (1 patent)Catherine PilletThierry Terme (1 patent)Catherine PilletPatrice Vanelle (1 patent)Catherine PilletSofia Giacosa (1 patent)Catherine PilletVincent Remusat (0 patent)Catherine PilletPatrice Vanelle (0 patent)Catherine PilletCatherine Pillet (2 patents)Caroline BaretteCaroline Barette (5 patents)Emmanuelle SoleilhacEmmanuelle Soleilhac (2 patents)Claude CochetClaude Cochet (5 patents)Odile FilholOdile Filhol (2 patents)Marie-Odile FauvarqueMarie-Odile Fauvarque (1 patent)Magda MortierMagda Mortier (1 patent)Carmen AguilarCarmen Aguilar (1 patent)Vincent RemusatVincent Remusat (1 patent)Thierry TermeThierry Terme (1 patent)Patrice VanellePatrice Vanelle (1 patent)Sofia GiacosaSofia Giacosa (1 patent)Vincent RemusatVincent Remusat (0 patent)Patrice VanellePatrice Vanelle (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives (2 from 4,872 patents)

2. Institut National De La Sante Et De La Recherche Medicale (1 from 1,743 patents)

3. Université´ D'aix-Marseille (1 from 229 patents)

4. Université Grenoble Alpes (1 from 152 patents)


2 patents:

1. 11306063 - Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease

2. 10322133 - Synthetic lethal drug combination for treating renal cell carcinoma

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/12/2025
Loading…